Phase II
Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.
A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.
In addition to the COVID-19 development, the company plans to use the proceeds toward its pipeline of highly selective direct acting antivirals that target other severe RNA virus infections.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 19, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
PRESS RELEASES